domingo, 1 de diciembre de 2013

Risk-reducing mastectomy in BRCA1/2 mutation carri... [Maturitas. 2013] - PubMed - NCBI

Risk-reducing mastectomy in BRCA1/2 mutation carri... [Maturitas. 2013] - PubMed - NCBI

Maturitas. 2013 Nov 1. pii: S0378-5122(13)00328-9. doi: 10.1016/j.maturitas.2013.10.017. [Epub ahead of print]

Risk-reducing mastectomy in BRCA1/2 mutation carriers: Factors influencing uptake and timing.


Departments of Epidemiology, University Medical Center, University of Groningen, Groningen, The Netherlands. Electronic address:



Strategies in case of high risk of breast cancer in BRCA1/2 mutation carriers are either intensive breast cancer screening or risk-reducing mastectomy (RRM). Both options have a high physical and psychosexual impact. The aim of this study is to investigate who chooses when to undergo RRM.


BRCA1/2 mutation carriers have been prospectively registered at the family cancer clinic between 1994 and 2011. Analyses were performed to assess the relation between characteristics of the BRCA1/2 mutation carriers and an earlier decision for RRM.


A cumulative percentage of 35.6% of all women chose to undergo RRM within the first five years after disclosure of DNA test results. Women needed less time to choose for RRM measured from the first visit, if they were younger than 50 years of age (hazard ratio (HR)=2.67, 95% confidence interval (CI)=1.30-5.48) or had a mother who had had breast cancer (HR=1.51 95% CI=1.04-2.18). Also, women needed less time to choose for RRM in case of a previous breast cancer (HR=2.25, 95% CI=1.55-3.27). After a previous unilateral therapeutic mastectomy as a treatment for breast cancer, women needed less time to choose for RRM of the contralateral breast (HR=2.69, 95% CI=1.29-5.62) compared to women who had had breast-conserving therapy.


BRCA1/2 mutation carriers aged under 50, having a mother with breast cancer, who had previous unilateral breast cancer and previous unilateral therapeutic mastectomy chose more often and earlier for RRM.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.


Breast neoplasms/prevention & control, Genes, BRCA1, Genes, BRCA2, Mastectomy, Risk reduction behavior, Time factors
[PubMed - as supplied by publisher]

No hay comentarios:

Publicar un comentario